The benefit of CDK4/6i in combination with standard endocrine therapy remains unfortunately still controversial for early stage BC patients and is being investigated in ongoing clinical trials (PALLAS, PENELOPE-B, EarLEE-1, MonarchE) (75). This evidence concerns the gene CDK4 and breast cancer.